Literature DB >> 18430913

Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis.

Jennifer Keiser1, Jürg Utzinger.   

Abstract

CONTEXT: More than a quarter of the human population is likely infected with soil-transmitted helminths (Ascaris lumbricoides, hookworm, and Trichuris trichiura) in highly endemic areas. Preventive chemotherapy is the mainstay of control, but only 4 drugs are available: albendazole, mebendazole, levamisole, and pyrantel pamoate.
OBJECTIVE: To assess the efficacy of single-dose oral albendazole, mebendazole, levamisole, and pyrantel pamoate against A lumbricoides, hookworm, and T trichiura infections. DATA SOURCES: A systematic search of PubMed, ISI Web of Science, ScienceDirect, the World Health Organization library database, and the Cochrane Central Register of Controlled Trials (1960 to August 2007). STUDY SELECTION: From 168 studies, 20 randomized controlled trials were included. DATA EXTRACTION AND DATA SYNTHESIS: Information on study year and country, sample size, age of study population, mean infection intensity before treatment, diagnostic method used, time between evaluations before and after treatment, cure rate (the percentage of individuals who became helminth egg negative following treatment with an anthelminthic drug), egg reduction rate, adverse events, and trial quality was extracted. Relative risk, including a 95% confidence interval (CI), was used to measure the effect of the drugs on the risk of infection prevalence with a random-effects model.
RESULTS: Single-dose oral albendazole, mebendazole, and pyrantel pamoate for infection with A lumbricoides resulted in cure rates of 88% (95% CI, 79%-93%; 557 patients), 95% (95% CI, 91%-97%; 309 patients), and 88% (95% CI, 79%-93%; 131 patients), respectively. Cure rates for infection with T trichiura following treatment with single-dose oral albendazole and mebendazole were 28% (95% CI, 13%-39%; 735 patients) and 36% (95% CI, 16%-51%; 685 patients), respectively. The efficacy of single-dose oral albendazole, mebendazole, and pyrantel pamoate against hookworm infections was 72% (95% CI, 59%-81%; 742 patients), 15% (95% CI, 1%-27%; 853 patients), and 31% (95% CI, 19%-42%; 152 patients), respectively. No pooled relative risks could be calculated for pyrantel pamoate against T trichiura and levamisole for any of the parasites investigated.
CONCLUSIONS: Single-dose oral albendazole, mebendazole, and pyrantel pamoate show high cure rates against A lumbricoides. For hookworm infection, albendazole was more efficacious than mebendazole and pyrantel pamoate. Treatment of T trichiura with single oral doses of current anthelminthics is unsatisfactory. New anthelminthics are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430913     DOI: 10.1001/jama.299.16.1937

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  321 in total

1.  Effects of annual mass treatment with ivermectin for onchocerciasis on the prevalence of intestinal helminths.

Authors:  Julie Gutman; Emmanuel Emukah; Njideka Okpala; Chinyere Okoro; Andrew Obasi; Emmanuel S Miri; Frank O Richards
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

2.  Prevalence of intestinal parasites versus knowledge, attitudes, and practices of inhabitants of low-income communities of Campos dos Goytacazes, Rio de Janeiro State, Brazil.

Authors:  Antonio Henrique A de Moraes Neto; Adriana P M F Pereira; Maria de Fátima L Alencar; Paulo R B Souza; Rodrigo C Dias; Juliana G Fonseca; Clóvis P Santos; João C A Almeida
Journal:  Parasitol Res       Date:  2010-04-21       Impact factor: 2.289

Review 3.  Developing vaccines to combat hookworm infection and intestinal schistosomiasis.

Authors:  Peter J Hotez; Jeffrey M Bethony; David J Diemert; Mark Pearson; Alex Loukas
Journal:  Nat Rev Microbiol       Date:  2010-11       Impact factor: 60.633

Review 4.  The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.

Authors:  Mandy Juarez; Alejandro Schcolnik-Cabrera; Alfonso Dueñas-Gonzalez
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

Review 5.  A history of hookworm vaccine development.

Authors:  Brent Schneider; Amar R Jariwala; Maria Victoria Periago; Maria Flávia Gazzinelli; Swaroop N Bose; Peter J Hotez; David J Diemert; Jeffrey M Bethony
Journal:  Hum Vaccin       Date:  2011-11-01

6.  Eight genes are required for functional reconstitution of the Caenorhabditis elegans levamisole-sensitive acetylcholine receptor.

Authors:  Thomas Boulin; Marc Gielen; Janet E Richmond; Daniel C Williams; Pierre Paoletti; Jean-Louis Bessereau
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-19       Impact factor: 11.205

7.  Mammalian metallopeptidase inhibition at the defense barrier of Ascaris parasite.

Authors:  Laura Sanglas; Francesc X Aviles; Robert Huber; F Xavier Gomis-Rüth; Joan L Arolas
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

8.  Randomized, controlled, assessor-blind clinical trial to assess the efficacy of single- versus repeated-dose albendazole to treat ascaris lumbricoides, trichuris trichiura, and hookworm infection.

Authors:  Ayola A Adegnika; Jeannot F Zinsou; Saadou Issifou; Ulysse Ateba-Ngoa; Roland F Kassa; Eliane N Feugap; Yabo J Honkpehedji; Jean-Claude Dejon Agobe; Hilaire M Kenguele; Marguerite Massinga-Loembe; Selidji T Agnandji; Benjamin Mordmüller; Michael Ramharter; Maria Yazdanbakhsh; Peter G Kremsner; Bertrand Lell
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

9.  The effects of immunostimulation through dietary manipulation in the rainbow trout; evaluation of mucosal immunity.

Authors:  Carmen Doñate; Joan Carles Balasch; Agnes Callol; Julien Bobe; Lluis Tort; Simon MacKenzie
Journal:  Mar Biotechnol (NY)       Date:  2009-07-16       Impact factor: 3.619

10.  Oxadiazole 2-oxides are toxic to the human hookworm, Ancylostoma ceylanicum, however glutathione reductase is not the primary target.

Authors:  R S Treger; A G Cook; G Rai; D J Maloney; A Simeonov; A Jadhav; C J Thomas; D L Williams; M Cappello; J J Vermeire
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-05-18       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.